Eligibility check
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
Step 1 of 5
Where are you located?
We confirm your state so we only show studies you can actually reach.
Your answers help match you to studies and connect you with the research team. They're handled per our Privacy Policy.